Ocugen company information, Employees & Contact Information

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results Yahoo Finance

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med Ocugen

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants Ocugen

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases Ocugen

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema Ocugen

Ocugen to Present at Industry and Investor Conferences in October 2025 Yahoo Finance

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease Yahoo Finance

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea GlobeNewswire

Ocugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness Diseases Quiver Quantitative

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 GlobeNewswire

Ocugen To Present at BIO International Convention 2025 GlobeNewswire

Ocugen Provides Business Update with Second Quarter 2025 Financial Results GlobeNewswire

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team GlobeNewswire

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease Yahoo Finance

Ocugen Provides Business Update with First Quarter 2025 Financial Results GlobeNewswire

Ocugen, Inc. Announces Signing of Binding Term Sheet for GlobeNewswire

Gene Therapy Pioneer Ocugen Takes Center Stage: CEO to Share FDA Strategy at Global Biotech Forums Stock Titan

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GlobeNewswire

Ocugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 Million Quiver Quantitative

Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan Stock Titan

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease GlobeNewswire

Ocugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson Investors Quiver Quantitative

Ocugen to Present on Modifier Gene Therapy Platform at GlobeNewswire

Revolutionary Gene Therapy Shows 48% Disease Slowdown in Stargardt Blindness Trial Stock Titan

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa Yahoo Finance

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal GlobeNewswire

Ocugen Announces Positive Opinion of European Medicines GlobeNewswire

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 GlobeNewswire

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations Ocugen

Ocugen Provides Business Update with First Quarter 2024 Financial Results Ocugen

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock Ocugen

Ocugen Secures $30 Million in Debt Funding Yahoo Finance

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy Ocugen

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop Ocugen

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial Ocugen

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication Ocugen

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 Ocugen

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152) Ocugen

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema Ocugen

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen

Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer Ocugen

Ocugen Secures $30 Million in Debt Funding GlobeNewswire

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart® Ocugen

Ocugen Provides Business Update & Second Quarter 2022 Financial Results Ocugen

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock Ocugen

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy Ocugen

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Ocugen

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Ocugen

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer Ocugen

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock Ocugen

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition Ocugen

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock Ocugen

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met Ocugen

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer Ocugen

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America Ocugen

Ocugen to Discontinue Phase 3 oGVHD Trial Ocugen

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada Ocugen

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152) Ocugen

Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market Ocugen

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance Ocugen

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Ocugen

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200 Ocugen

Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market Ocugen

Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule Ocugen

Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing Ocugen

Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Ocugen

Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer Ocugen

Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease Ocugen

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease Ocugen

Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease Ocugen

Ocugen, Inc. Announces Proposed Public Offering of Common Stock Yahoo Finance

Ocugen Appoints Huma Qamar, MD, MPH as Chief Medical Officer citybiz

Ocugen, Inc. Provides an Update on its Investigational New GlobeNewswire

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152) Yahoo Finance

Dr. Huma Qamar - Ocugen - 06/14/24 FOX 47 News

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial GlobeNewswire

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™ GlobeNewswire

Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease PR Newswire

Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease PR Newswire